Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 13
2003 11
2004 6
2005 11
2006 10
2007 11
2008 8
2009 7
2010 16
2011 11
2012 15
2013 14
2014 13
2015 7
2016 15
2017 9
2018 19
2019 19
2020 19
2021 15
Text availability
Article attribute
Article type
Publication date

Search Results

218 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.
Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E; PIONEER 8 Investigators. Zinman B, et al. Among authors: araki e. Diabetes Care. 2019 Dec;42(12):2262-2271. doi: 10.2337/dc19-0898. Epub 2019 Sep 17. Diabetes Care. 2019. PMID: 31530667 Free PMC article. Clinical Trial.
FoxK1 and FoxK2 in insulin regulation of cellular and mitochondrial metabolism.
Sakaguchi M, Cai W, Wang CH, Cederquist CT, Damasio M, Homan EP, Batista T, Ramirez AK, Gupta MK, Steger M, Wewer Albrechtsen NJ, Singh SK, Araki E, Mann M, Enerbäck S, Kahn CR. Sakaguchi M, et al. Among authors: araki e. Nat Commun. 2019 Apr 5;10(1):1582. doi: 10.1038/s41467-019-09418-0. Nat Commun. 2019. PMID: 30952843 Free PMC article.
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, Araki E, Lind M, Bain SC, Jabbour S, Arya N, Hansen L, Thorén F, Langkilde AM; DEPICT-2 Investigators. Mathieu C, et al. Among authors: araki e. Diabetes Care. 2018 Sep;41(9):1938-1946. doi: 10.2337/dc18-0623. Epub 2018 Jul 19. Diabetes Care. 2018. PMID: 30026335 Free article. Clinical Trial.
Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T; J-DOIT3 Study Group. Ueki K, et al. Lancet Diabetes Endocrinol. 2017 Dec;5(12):951-964. doi: 10.1016/S2213-8587(17)30327-3. Epub 2017 Oct 24. Lancet Diabetes Endocrinol. 2017. PMID: 29079252 Clinical Trial.
Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan.
Tateishi R, Matsumura T, Okanoue T, Shima T, Uchino K, Fujiwara N, Senokuchi T, Kon K, Sasako T, Taniai M, Kawaguchi T, Inoue H, Watada H, Kubota N, Shimano H, Kaneko S, Hashimoto E, Watanabe S, Shiota G, Ueki K, Kashiwabara K, Matsuyama Y, Tanaka H, Kasuga M, Araki E, Koike K; LUCID study investigators. Tateishi R, et al. Among authors: araki e. J Gastroenterol. 2021 Mar;56(3):261-273. doi: 10.1007/s00535-020-01754-z. Epub 2021 Jan 11. J Gastroenterol. 2021. PMID: 33427937 Free PMC article.
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Mathieu C, Rudofsky G, Phillip M, Araki E, Lind M, Arya N, Thorén F, Scheerer MF, Iqbal N, Dandona P. Mathieu C, et al. Among authors: araki e. Diabetes Obes Metab. 2020 Sep;22(9):1516-1526. doi: 10.1111/dom.14060. Epub 2020 May 22. Diabetes Obes Metab. 2020. PMID: 32311204 Free PMC article. Clinical Trial.
SIRT7 controls hepatic lipid metabolism by regulating the ubiquitin-proteasome pathway.
Yoshizawa T, Karim MF, Sato Y, Senokuchi T, Miyata K, Fukuda T, Go C, Tasaki M, Uchimura K, Kadomatsu T, Tian Z, Smolka C, Sawa T, Takeya M, Tomizawa K, Ando Y, Araki E, Akaike T, Braun T, Oike Y, Bober E, Yamagata K. Yoshizawa T, et al. Among authors: araki e. Cell Metab. 2014 Apr 1;19(4):712-21. doi: 10.1016/j.cmet.2014.03.006. Cell Metab. 2014. PMID: 24703702 Free article.
Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry).
Ueki K, Tanizawa Y, Nakamura J, Yamada Y, Inagaki N, Watada H, Shimomura I, Nishimura R, Miyoshi H, Abiko A, Katagiri H, Hayashi M, Shimada A, Naruse K, Fujimoto S, Fujiwara M, Shikata K, Okada Y, Araki E, Yamazaki T, Kadowaki T; J-BRAND Registry Group. Ueki K, et al. Among authors: araki e. BMJ Open Diabetes Res Care. 2021 Jan;9(1):e001787. doi: 10.1136/bmjdrc-2020-001787. BMJ Open Diabetes Res Care. 2021. PMID: 33441417 Free PMC article.
New perspectives on insulin therapy.
Araki E, Araki H, Senokuchi T, Motoshima H. Araki E, et al. J Diabetes Investig. 2020 Jul;11(4):795-797. doi: 10.1111/jdi.13263. Epub 2020 May 21. J Diabetes Investig. 2020. PMID: 32232932 Free PMC article. No abstract available.
218 results